ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,713 | -87.6% | 328 | -88.2% | 0.00% | -87.5% |
| Q2 2023 | $247,847 | +134599.5% | 2,777 | +61.5% | 0.01% | +33.3% |
| Q1 2023 | $184 | -24.9% | 1,719 | -14.3% | 0.01% | -40.0% |
| Q4 2022 | $245 | -99.8% | 2,005 | +96.0% | 0.01% | +400.0% |
| Q3 2022 | $106,000 | -72.2% | 1,023 | -75.0% | 0.00% | -77.8% |
| Q2 2022 | $381,000 | +27.4% | 4,094 | +60.9% | 0.01% | +200.0% |
| Q1 2022 | $299,000 | -33.3% | 2,545 | -23.5% | 0.00% | -62.5% |
| Q4 2021 | $448,000 | +293.0% | 3,325 | +364.4% | 0.01% | +166.7% |
| Q3 2021 | $114,000 | -69.1% | 716 | -74.5% | 0.00% | -70.0% |
| Q2 2021 | $369,000 | +1319.2% | 2,805 | +1316.7% | 0.01% | – |
| Q1 2021 | $26,000 | -68.7% | 198 | -60.2% | 0.00% | -100.0% |
| Q4 2020 | $83,000 | +130.6% | 498 | +114.7% | 0.00% | – |
| Q3 2020 | $36,000 | -93.7% | 232 | -94.0% | 0.00% | -100.0% |
| Q2 2020 | $567,000 | +990.4% | 3,838 | +736.2% | 0.02% | +666.7% |
| Q1 2020 | $52,000 | -50.9% | 459 | -49.9% | 0.00% | -57.1% |
| Q2 2019 | $106,000 | -38.7% | 916 | -37.9% | 0.01% | -30.0% |
| Q1 2019 | $173,000 | +2062.5% | 1,476 | +1183.5% | 0.01% | – |
| Q2 2018 | $8,000 | +700.0% | 115 | +784.6% | 0.00% | – |
| Q1 2018 | $1,000 | -50.0% | 13 | -77.2% | 0.00% | – |
| Q3 2017 | $2,000 | – | 57 | – | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2017 | $32,000 | +166.7% | 1,133 | +86.0% | 0.00% | +200.0% |
| Q4 2016 | $12,000 | -29.4% | 609 | -27.4% | 0.00% | -50.0% |
| Q3 2016 | $17,000 | -19.0% | 839 | -47.5% | 0.00% | 0.0% |
| Q2 2016 | $21,000 | +600.0% | 1,599 | +813.7% | 0.00% | – |
| Q3 2015 | $3,000 | – | 175 | +1066.7% | 0.00% | – |
| Q2 2015 | $0 | -100.0% | 15 | -98.9% | 0.00% | -100.0% |
| Q1 2015 | $23,000 | – | 1,323 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |